Literature DB >> 9557757

Identification of hepatitis G virus particles in human serum by E2-specific monoclonal antibodies generated by DNA immunization.

S Schmolke1, M Tacke, U Schmitt, A M Engel, B Ofenloch-Haehnle.   

Abstract

In order to elucidate the structure and morphology of hepatitis G virus (HGV), a recently isolated flavivirus, we generated a panel of eight monoclonal antibodies (MAbs) against the putative second envelope protein (E2) following DNA immunization. The MAbs were shown to be specific for four different epitopes on recombinant E2. MAb Mc6 was the only antibody able to detect the linear epitope LTGGFYEPL. In addition, Mc6 was able to immunoprecipitate viral particles in human blood samples as detected by reverse transcription-PCR amplification of HGV RNA. This precipitation could be competed by addition of saturating amounts of the linear peptide or abolished by addition of Nonidet P-40. We conclude that, albeit lacking the N-terminal sequence of a functional core protein, HGV builds classical viral particles displaying E2 envelope protein on their outer surfaces.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557757      PMCID: PMC109705          DOI: 10.1128/JVI.72.5.4541-4545.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Translation initiation in GB viruses A and C: evidence for internal ribosome entry and implications for genome organization.

Authors:  J N Simons; S M Desai; D E Schultz; S M Lemon; I K Mushahwar
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

2.  Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery.

Authors:  T M Pertmer; T R Roberts; J R Haynes
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

3.  Buoyant density of hepatitis C virus recovered from infected hosts: two different features in sucrose equilibrium density-gradient centrifugation related to degree of liver inflammation.

Authors:  T Kanto; N Hayashi; T Takehara; H Hagiwara; E Mita; M Naito; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1994-02       Impact factor: 17.425

4.  Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization.

Authors:  E Raz; H Tighe; Y Sato; M Corr; J A Dudler; M Roman; S L Swain; H L Spiegelberg; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

5.  Sequence and genomic organization of GBV-C: a novel member of the flaviviridae associated with human non-A-E hepatitis.

Authors:  T P Leary; A S Muerhoff; J N Simons; T J Pilot-Matias; J C Erker; M L Chalmers; G G Schlauder; G J Dawson; S M Desai; I K Mushahwar
Journal:  J Med Virol       Date:  1996-01       Impact factor: 2.327

6.  Association of hepatitis C virus in human sera with beta-lipoprotein.

Authors:  R Thomssen; S Bonk; C Propfe; K H Heermann; H G Köchel; A Uy
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

7.  Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes.

Authors:  M Hijikata; Y K Shimizu; H Kato; A Iwamoto; J W Shih; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent.

Authors:  J Linnen; J Wages; Z Y Zhang-Keck; K E Fry; K Z Krawczynski; H Alter; E Koonin; M Gallagher; M Alter; S Hadziyannis; P Karayiannis; K Fung; Y Nakatsuji; J W Shih; L Young; M Piatak; C Hoover; J Fernandez; S Chen; J C Zou; T Morris; K C Hyams; S Ismay; J D Lifson; G Hess; S K Foung; H Thomas; D Bradley; H Margolis; J P Kim
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

9.  The physical state of the negative strand of hepatitis C virus RNA in serum of patients with chronic hepatitis C.

Authors:  M Shindo; A M Di Bisceglie; T Akatsuka; T L Fong; L Scaglione; M Donets; J H Hoofnagle; S M Feinstone
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

10.  Infection with hepatitis GB virus C in patients on maintenance hemodialysis.

Authors:  K Masuko; T Mitsui; K Iwano; C Yamazaki; K Okuda; T Meguro; N Murayama; T Inoue; F Tsuda; H Okamoto; Y Miyakawa; M Mayumi
Journal:  N Engl J Med       Date:  1996-06-06       Impact factor: 91.245

View more
  6 in total

1.  In vitro infection of human peripheral blood mononuclear cells by GB virus C/Hepatitis G virus.

Authors:  M Fogeda; S Navas; J Martín; M Casqueiro; E Rodríguez; C Arocena; V Carreño
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding.

Authors:  James H McLinden; Thomas M Kaufman; Jinhua Xiang; Qing Chang; Donna Klinzman; Alfred M Engel; Georg Hess; Urban Schmidt; Michael Houghton; Jack T Stapleton
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

3.  GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates.

Authors:  Emma L Mohr; Jinhua Xiang; James H McLinden; Thomas M Kaufman; Qing Chang; David C Montefiori; Donna Klinzman; Jack T Stapleton
Journal:  J Immunol       Date:  2010-09-08       Impact factor: 5.422

Review 4.  Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease?

Authors:  Jack T Stapleton
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

Review 5.  GB virus type C interactions with HIV: the role of envelope glycoproteins.

Authors:  Emma L Mohr; Jack T Stapleton
Journal:  J Viral Hepat       Date:  2009-09-15       Impact factor: 3.728

Review 6.  DNA immunization as a technology platform for monoclonal antibody induction.

Authors:  Shuying Liu; Shixia Wang; Shan Lu
Journal:  Emerg Microbes Infect       Date:  2016-04-06       Impact factor: 7.163

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.